Answers are grounded in this paper and cite their sources.
Case report demonstrates a complete response to cemiplimab in cutaneous squamous cell carcinoma with HIV, highlighting immunotherapy safety and efficacy in immunocompromised settings.
This is a case of a 60-year-old man living with HIV who presented with advanced cutaneous squamous cell carcinoma. After workup, medical and surgical treatment, and disease recurrence, he achieved a complete response with no unexpected toxicities after immunotherapy with cemiplimab.
No takes yet. Share an insight, caveat, or question.
Alloghbi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: